Finoriq research workspace
Absci Corp (ABSI) SEC Filings & Filing Highlights
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody. Review ABSI SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- Company
- Absci Corp (ABSI)
- Ticker
- ABSI
- Market Cap
- $1.3B
- Latest Price
- $8.15
- Industry
- Biotech & Pharma
Absci Corp (ABSI) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Absci Corp (ABSI).
| Event | Form | Date |
|---|---|---|
| Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financ...Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors | 8-K8.01 | 2026-06-24 |
| The Shares will be sold to the purchasers at an offering price of $7.41 per shareOn June 24, 2026, Absci Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LL... | 8-K1.01 | 2026-06-24 |
| Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Anti...Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) | 8-K8.01 | 2026-06-24 |
| Class II Director NomineesAbsci Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 4, 2026. As of April 7, 2026, the... | 8-K5.07 | 2026-06-05 |
| Absci Reports Business Updates and First Quarter 2026 Financial and Operating ResultsAbsci Reports Business Updates and First Quarter 2026 Financial and Operating Results | 8-K8.01 | 2026-05-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.